Related Experiment Video

Updated: Sep 5, 2025

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.0K

ILP-2: A New Bane and Therapeutic Target for Human Cancers

Zhiliang Zhang1,2, Siqi Xiang1,2, Ruxia Cui1,2

  • 1Department of Biochemistry and Immunology, Medical Research Center, Institute of Medicine, Jishou University, Jishou, China.

Frontiers in Oncology
|July 11, 2022
PubMed

Insights

Inhibitor of apoptosis protein-related-like protein-2 (ILP-2) promotes cancer growth and drug resistance. Targeting ILP-2 offers a novel therapeutic strategy by enhancing apoptosis and sensitizing tumors to chemotherapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Death Research

Background:

  • Inhibitor of apoptosis protein-related-like protein-2 (ILP-2), also known as BIRC-8, is a key negative regulator of apoptosis.
  • ILP-2 is overexpressed in various human tumors, contributing to tumor progression and chemoresistance.

Purpose of the Study:

  • To review the role of ILP-2 in the apoptotic cascade.
  • To explore ILP-2 interference as a novel cancer therapy strategy.

Main Methods:

  • Literature review of studies on ILP-2 function and therapeutic potential.
  • Analysis of ILP-2's unique mechanism of apoptosis inhibition.

Main Results:

  • ILP-2 overexpression promotes tumor cell survival, growth, aggressiveness, and chemotherapeutic resistance.
  • Downregulation of ILP-2 enhances apoptosis, inhibits metastasis, and sensitizes cancer cells to chemotherapy.
  • ILP-2 inhibits apoptosis indirectly by interacting with other apoptosis-related proteins, not by direct caspase inhibition.

Conclusions:

  • ILP-2 plays a significant role in cancer progression and treatment resistance.
  • Targeting ILP-2, potentially in combination with other anti-cancer agents, represents a promising novel therapeutic approach for cancer treatment.
Keywords:
IAPSILP-2apoptosiscaspasesmigrationtumor therapy

More Related Videos

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

3.3K
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
652
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K